Related references
Note: Only part of the references are listed.Dasatinib-therapy induced sustained remission in a child with refractory TCF7-SPI1 T-cell acute lymphoblastic leukemia
Yingyi He et al.
PEDIATRIC BLOOD & CANCER (2022)
Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs
Jaeki Min et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations
Maryam Shariati et al.
ONCOGENE (2021)
Targeted protein degradation: A promise for undruggable proteins
Kusal T. G. Samarasinghe et al.
CELL CHEMICAL BIOLOGY (2021)
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia
Yoshihiro Gocho et al.
NATURE CANCER (2021)
Fundamental aspects of DMPK optimization of targeted protein degraders
Carina Cantrill et al.
DRUG DISCOVERY TODAY (2020)
Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown
Yu-Hui Jin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL
Bingqi Tong et al.
ACS CHEMICAL BIOLOGY (2020)
Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma
Bachar Samra et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects
Yiqing Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase
Bikash Adhikari et al.
NATURE CHEMICAL BIOLOGY (2020)
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development
Katherine A. Donovan et al.
CELL (2020)
Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia
David T. Teachey et al.
LANCET ONCOLOGY (2019)
Targeted protein degradation: elements of PROTAC design
Stacey-Lynn Paiva et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2019)
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
William Farnaby et al.
NATURE CHEMICAL BIOLOGY (2019)
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Katrin Mestermann et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase
Quanju Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
Xin Han et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Sajid Khan et al.
NATURE MEDICINE (2019)
Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
Ian Churcher
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Strelka2: fast and accurate calling of germline and somatic variants
Sangtae Kim et al.
NATURE METHODS (2018)
Regulatory mechanisms in T cell receptor signalling
Guillaume Gaud et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP
Maoxiang Qian et al.
GENOME RESEARCH (2017)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells
Robin M. Meyers et al.
NATURE GENETICS (2017)
The target landscape of clinical kinase drugs
Susan Klaeger et al.
SCIENCE (2017)
In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL
S. Laukkanen et al.
BLOOD CANCER JOURNAL (2017)
Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia
Valentina Serafin et al.
BLOOD (2017)
Discoidin domain receptor 1 activity drives an aggressive phenotype in gastric carcinoma
Hoon Hur et al.
BMC CANCER (2017)
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
Ashton C. Lai et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Mary E. Matyskiela et al.
NATURE (2016)
Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma
Chiara Ambrogio et al.
NATURE MEDICINE (2016)
T-cell acute lymphoblastic leukemia
Elizabeth A. Raetz et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data
Yu Fan et al.
GENOME BIOLOGY (2016)
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lu et al.
CHEMISTRY & BIOLOGY (2015)
Catalytic in vivo protein knockdown by small-molecule PROTACs
Daniel P. Bondeson et al.
NATURE CHEMICAL BIOLOGY (2015)
Acute Lymphoblastic Leukemia in Children
Stephen P. Hunger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter et al.
SCIENCE (2015)
Systematic Optimization of Long Gradient Chromatography Mass Spectrometry for Deep Analysis of Brain Proteome
Hong Wang et al.
JOURNAL OF PROTEOME RESEARCH (2015)
JUMP: A Tag-based Database Search Tool for Peptide Identification with High Sensitivity and Accuracy
Xusheng Wang et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
SomaticSniper: identification of somatic point mutations in whole genome sequencing data
David E. Larson et al.
BIOINFORMATICS (2012)
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
Daniel C. Koboldt et al.
GENOME RESEARCH (2012)
Identification of Receptor Tyrosine Kinase, Discoidin Domain Receptor 1 (DDR1), as a Potential Biomarker for Serous Ovarian Cancer
Jinhua Quan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
The Sequence Alignment/Map format and SAMtools
Heng Li et al.
BIOINFORMATICS (2009)
Fast and accurate short read alignment with Burrows-Wheeler transform
Heng Li et al.
BIOINFORMATICS (2009)
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)
David I. Marks et al.
BLOOD (2009)
Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study
K. Nguyen et al.
LEUKEMIA (2008)
A modified fast (4 day) 96-well plate Caco-2 permeability assay
Masashi Uchida et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2008)
Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia
Nuno R. dos Santos et al.
BLOOD (2007)
High throughput microsomal stability assay for insoluble compounds
Li Di et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2006)
The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants
John S. Tokarski et al.
CANCER RESEARCH (2006)
KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs)
Jerzy Lasota et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2006)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Cytokine-induced Src homology 2 protein (CIS) promotes T cell receptor-mediated proliferation and prolongs survival of activated T cells
SL Li et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
